Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Amgen's weight loss drug Maritide fell short of expectations, with only a 20% weight loss reported, causing a drop in the company's shares. In other news, Sarepta made a significant commitment of up to $10 billion in a deal with Arrowhead to expand its pipeline with RNA drugs. Roche also made a strategic move by acquiring Poseida for up to $1.5 billion, but faced a setback with a Phase III failure for its TIGIT asset. Alector's Alzheimer's program suffered a setback with a failed Phase II trial, leading to a 17% layoff. Lilly encountered legal challenges related to GLP-1 shortages, while AstraZeneca celebrated success with its Truqap in a Phase III prostate cancer trial.These developments are reshaping the landscape of the biotech industry, offering new opportunities in roles such as manufacturing engineer, associate director of preclinical development, data analyst scientist, and executive director of marketing. Stay informed with more news and updates on Biospace's website.